DALE Pharma SRL
Ouverture de faillite 17.6 FTEDALE Pharma reported revenue of €3.28m for the 2023 financial year (annual accounts filed with the NBB on 15 Aug 2024), with 17.6 full-time equivalents.
The score of DALE Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2023
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
DALE Pharma's annual accounts
| 2023 | |
|---|---|
| Revenue | €3.28m |
| Net result | 716 € |
| Equity | 606,013 € |
| Cash | 33,594 € |
| EBITDA | 94,579 € |
| Total assets | €3.08m |
Filed annual accounts
- Year ended 31 Dec 2023filed on 15 Aug 2024
DALE Pharma's financial analysis
- Solvency19.6%sector median: 31.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of DALE Pharma
DALE Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0791.839.803
- VAT number
- BE0791839803
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SRL
- Incorporated
- 04 Oct 2022
- Registered office
- 7850 Enghien
- Size
- Small · 17.6 FTE
- Latest accounts
- 2023 · filed on 15 Aug 2024
- Activity
- Other non-specialised retail sale (NACE 47120)
DALE Pharma (SRL) has been based in Enghien since 2022, active in: other non-specialised retail sale. For 2023, it reports revenue of €3.28m, a net profit of 716 € and equity of 606,013 €. With 17.6 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 19.6%, below the median of its sector (31.1%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to DALE Pharma
Companies in the same business, of comparable size and area, outside its group.
- Tecuma Retail sale of other food Uccle · balance sheet 34,070 €
- Apotheek LUX Retail sale of pharmaceutical products Sint-Truiden · balance sheet €3.04m
- Pharmacie de Warsage Retail sale of pharmaceutical products Dalhem · balance sheet €3.38m
- Medifarm+ Retail sale of pharmaceutical products Bruges · balance sheet €2.75m
- Albanimmo Retail sale of pharmaceutical products Grez-Doiceau · balance sheet €2.53m
- Edis Invest Retail sale of pharmaceutical products Molenbeek-Saint-Jean · balance sheet €2.26m
- Limafran Retail sale of pharmaceutical products Lincent · balance sheet €2.00m
- Mafapara Retail sale of medical and orthopaedic goods Gembloux · balance sheet €1.64m
Frequently asked questions about DALE Pharma
What is the revenue of DALE Pharma?
According to the 2023 annual accounts filed with the NBB, the revenue of DALE Pharma amounts to 3,283,638 €.
What is the VAT number of DALE Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0791839803 for DALE Pharma, if the company is VAT-registered. Its company number (CBE) is 0791.839.803.
Where is the registered office of DALE Pharma?
According to the CBE register, the registered office of DALE Pharma is in 7850 Enghien.
What is the equity of DALE Pharma?
At the close of the 2023 financial year, the equity of DALE Pharma amounts to 606,013 €, a solvency of 19.6% of total assets.
How many people work at DALE Pharma?
17.6 full-time equivalents on average according to the 2023 social balance sheet.
Who manages DALE Pharma?
The register lists 3 active mandates at DALE Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of DALE Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →